# A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

> **NCT01196091** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1164 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Connective Tissue Disease
- Autoimmune Disease

## Interventions

- **DRUG:** LY2127399
- **DRUG:** Placebo every 2 weeks
- **DRUG:** Placebo every 4 weeks
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT01196091
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-07
- **Final completion:** 2015-06
- **Target enrollment:** 1164 (ACTUAL)
- **Last updated:** 2018-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01196091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01196091, "A Study of LY2127399 in Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01196091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*